Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
Sotio Biotech Inc.
Mayo Clinic
Immunocore Ltd
Dana-Farber Cancer Institute
Emory University
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of California, Davis
Teva Branded Pharmaceutical Products R&D, Inc.
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University of Chicago
Massachusetts General Hospital
Highlight Therapeutics
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
MacroGenics
Yale University
Herlev Hospital
Providence Health & Services
Mayo Clinic
University of Chicago
Mural Oncology, Inc
Seagen Inc.
Syndax Pharmaceuticals
GlaxoSmithKline
Seagen Inc.
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Amgen
University of Pennsylvania
Merck Sharp & Dohme LLC
Immodulon Therapeutics Ltd
Abramson Cancer Center at Penn Medicine
University of Pittsburgh
Hoosier Cancer Research Network
University of Colorado, Denver
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC